scispace - formally typeset
Search or ask a question
Author

Georges Haas

Bio: Georges Haas is an academic researcher from Novartis. The author has contributed to research in topics: Alkyl & Phenylene. The author has an hindex of 9, co-authored 27 publications receiving 252 citations.
Topics: Alkyl, Phenylene, Trifluoromethyl, Thio-, Alkoxy group

Papers
More filters
Journal ArticleDOI
TL;DR: In this article, the pyridine ring forming reactions are discussed and the factors determining the formation and regiospecificity of the ring-forming reactions are also discussed, as well as the properties of pyridines.

61 citations

Journal ArticleDOI
TL;DR: The reactions of 3-formylchromone (1) with 1, 2-phenylenediamine, 2amino-diphenylamine and 2-aminophenol were reinvestigated and shown to yield 1, 8-dihydro-6, 13-di (2-hydroxybenzoyl)-dibenzo [b, i]-l, 4, 8, 11-tetraazacyclotetradeca- 4, 6, 11,13-Tetraene (7), 3-[2
Abstract: The reactions of 3-formylchromone (1) with 1, 2-phenylenediamine, 2-amino-diphenylamine and 2-aminophenol were reinvestigated and shown to yield 1, 8-dihydro-6, 13-di (2-hydroxybenzoyl)-dibenzo [b, i]-l, 4, 8, 11-tetraazacyclotetradeca- 4, 6, 11,13-tetraene (7), 3-[2-(1-phenyl)benzimidazolyl]chromone (10b) and 3-(2-hydroxyphenyl)iminomethylchromone (4), respectively at variance with earlier reports. Compound 4 reacts with ethanol to give 2-ethoxy-3-[(2-hydroxyphenyl)-aminomethylidene]chroman-4-one (5b). Dehydrogenation of 7 produces 3-(2-benz-imidazolyl)chromone (10a), also at variance with earlier reports. The structures have been elucidated with the aid of NMR. and mass spectra. The reaction mechanism is discussed.

55 citations

Journal ArticleDOI
TL;DR: In this paper, 3-Nitrochromone (1) reacts with a series of nucleophiles by Michael addition followed by intramolecular condensation to yield pyrrolyl (2), phenyl (3), pyridyl (4, pyrido (5,6), pyrimidyl(7), and pyrazolyl (8) nitro derivatives.

24 citations

Patent
06 May 1974
TL;DR: In this article, the authors defined the SPC1, where Ph denotes a 1,2-phenylene radical which carries cyclo-aliphatic radical, R x denotes a free or etherified hydroxyl group or a free substituted amino group, R o denotes an alkyl radical, a free hydrastic group and R 1 denotes a hydrogen atom.
Abstract: ##SPC1## wherein Ph denotes a 1,2-phenylene radical which carries cycloaliphatic radical, R x denotes a free or etherified hydroxyl group or a free or substituted amino group, R o denotes an alkyl radical, a free hydroxyl group or a hydroxyl group etherified by lower alkyl or, above all, a hydrogen atom and R 1 denotes an aliphatic or cycloaliphatic hydrocarbon radical which is optionally substituted by hydroxyl, an araliphatic radical or a hydrogen atom, and their salts, which possess valuable analgesic, anti-inflammatory, anti-microbial and histamine liberation inhibiting properties.

22 citations

Journal ArticleDOI
TL;DR: In this paper, all four possible diastereomeric α-phenylethylamides of biphenyl-2,2′, 6,6′-tetra-carboxylic acid (point symmetries D2, S4, C2 and C1) have been prepared and their properties investigated.
Abstract: All four possible diastereomeric α-phenylethylamides of biphenyl-2,2′, 6,6′-tetra-carboxylic acid (point symmetries D2, S4, C2 and C1) have been prepared and their properties investigated. Both enantiomers of the C2-diastereomer have been synthetized along stereospecific routes which determine their absolute configurations. Specification of molecular chirality and pseudoasymmetry of compounds with axial chirality in two and three dimensional space is discussed.

17 citations


Cited by
More filters
Patent
25 Feb 2004
TL;DR: In this article, an invention related to inhibitors of p38, and methods for producing these inhibitors are described. And pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders mediated by p38 are provided.
Abstract: This invention relates to inhibitors of p38, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders mediated by p38.

326 citations

Patent
11 Mar 1999
TL;DR: In this paper, the authors present novel compounds, novel compositions, methods of their use, and methods for their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1,SHP-2, PTPα, LAR and HePTP or the like.
Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

276 citations

Journal ArticleDOI
TL;DR: In this article, a review of vertically expanded coumarins is presented, which serves as a guide through both synthesis strategies and structure-property relationship nuances, including the mode of fusion, the type of additional ring and the presence of electron-donating and electron-withdrawing substituents.
Abstract: Coumarins fused with other aromatic units have recently emerged as a hot topic of research. Their synthesis is partly based on classical methodologies such as Pechmann reaction or Knoevenagel condensation, but it also sparked the discovery of completely new pathways. In very recent years so-called vertically expanded coumarins were synthesized, effectively expanding the portfolio of existing architectures. A subtle relationship exists between the structure of fused coumarins and their optical properties. Although absorption of UV-radiation and light is a unifying theme among these π-expanded coumarins, the fluorescence properties strongly depend on the structure. The mode of fusion, the type of additional ring and the presence of electron-donating and electron-withdrawing substituents all influence the photophysical parameters. Recent advances made it possible to modulate their absorption from 300 nm to 550 nm, resulting in new coumarins emitting orange light. This review serves as a guide through both synthesis strategies and structure–property relationship nuances. Strong intramolecular charge-transfer character made it possible to reach suitable values of two-photon absorption cross-section. Photophysical advantages of π-expanded coumarins have been already utilized in fluorescent probes and two-photon excited fluorescence microscopy.

187 citations

Journal ArticleDOI
TL;DR: Compounds 4b-c/5a-c and 9a demonstrated in vitro antitumor activity against P388 leukemia and Antineoplastic activity of the compounds 4b/5b and9a combined with methotrexate was showed using L1210 murine leukemia.

172 citations

Book ChapterDOI
TL;DR: In this article, the chemistry and pharmacology and physicochemical properties of barbiturates, along with the tautomerism and solvation of the Barbituric acid ring are discussed.
Abstract: Publisher Summary This chapter provides information on the chemistry and pharmacology and physicochemical properties of barbiturates, along with the tautomerism and solvation of the barbituric acid ring. Barbituric acid exists in the solid state in the trioxo structure. NMR investigation of the oxo-hydroxy equilibrium indicates that only the oxo form is present in a solution in anhydrous DMSO. Several spectral properties of the barbituric acid are discussed using UV spectra, infrared and Raman spectroscopy, 1 H-NMR spectroscopy, 13 C-NMR spectroscopy, and mass spectrometry. In the crystalline state, barbiturates show several modes of intermolecular hydrogen bonding, which differ by the number of hydrogen bonds formed between the NH and CO groups. These hydrogen bonds are responsible for layer packing in the crystal lattice. Weak intermolecular van der Waals interactions of carbonyl groups are also responsible for the three-dimensional packing of the molecules in the crystal structure.

155 citations